Casirivimab/imdevimab
Casirivimab/Imdevimab
Casirivimab/Imdevimab (pronunciation: kuh-sir-uh-vim-ab/im-dev-im-ab) is a combination of two monoclonal antibodies used for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in certain patients.
Etymology
The names "Casirivimab" and "Imdevimab" are derived from the International Nonproprietary Names (INN) system, which is used to name pharmaceutical substances. The "-vimab" suffix is used for monoclonal antibodies.
Usage
Casirivimab and imdevimab are administered together for the treatment of COVID-19 in individuals who are at high risk for progressing to severe COVID-19 and/or hospitalization. This includes those who are 65 years of age or older, or who have certain chronic medical conditions.
Mechanism of Action
Casirivimab and imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.
Related Terms
External links
- Medical encyclopedia article on Casirivimab/imdevimab
- Wikipedia's article - Casirivimab/imdevimab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski